Skip to content
Review Open access

Ferula assafoetida as a Multi-Target Therapeutic Candidate for Parkinson's Disease: A Narrative Review

Aug 2026 · Journal of Tropical Life Science · Vol 16, pp. 217-234 · 0 citations

TL;DR

This review evaluates the therapeutic potential of the ayurvedic plant, Ferula assafoetida, as a candidate for PD treatment and lays the groundwork for exploring F. assafoetida as a viable preclinical candidate.

Abstract

Parkinson’s disease (PD) presents a complex challenge in neurodegenerative research due to the persistent lack of disease-modifying therapies, prompting exploration of natural compounds with multi-target capabilities to modulate multiple pathways. Hence, this review evaluates the therapeutic potential of the ayurvedic plant, Ferula assafoetida, as a candidate for PD treatment. The phytochemical profile of F. assafoetida, rich in bioactive sulfur volatiles, phenolic acids, coumarins, and terpenes, aligns with mechanisms implicated in PD pathogenesis, including oxidative stress, inflammation, and mitochondrial dysfunction. Critically, recent activity-guided isolation studies have successfully identified specific sesquiterpene coumarins, such as karatavicinol and farnesiferol C, as potent monoamine oxidase-B (MAO-B) inhibitors, demonstrating efficacy in ameliorating motor deficits and protecting dopaminergic neurons in a murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. This breakthrough provides the first direct experimental evidence for F. assafoetida in a PD model, transitioning its status from a traditional remedy to a source of validated, bioactive lead compounds. While mammalian models offer crucial translational validation, zebrafish, with their conserved dopaminergic pathways, genetic tractability, and suitability for high-throughput screening, emerge as an ideal complementary platform for accelerating future research. Advanced phytochemical profiling, integrating chromatographic methods and in silico molecular docking, could prioritize lead compounds for further investigation. The integration of gene expression analysis in zebrafish models, alongside behavioral assays, enables a comprehensive understanding of the impact of this plant on PD-related pathways. This pertinent evidence now positions F. assafoetida as a viable preclinical candidate. Future research should prioritize chemical standardization across different plant sources and in vivo mechanistic studies in zebrafish. By illustrating the synergy between phytochemistry and innovative model systems, this review lays the groundwork for exploring F. assafoetida as a promising candidate for novel PD therapies and related neurodegenerative disorders.

Read PDF

Similar papers

Review Jul 2026

Integrative Phytotherapy for Neurodegenerative Disorders: Bridging Traditional Botanicals, Bioactive Compounds, and Nanotechnology.

Neurodegenerative disorders (NDDs) such as Alzheimer's, Parkinsons etc., are progressive and debilitating conditions that have little therapeutic intervention. Existing pharmacological interventions mainly provide symptomatic relief and do not respond to the pathophysiology of these diseases, which is complex and multi...

Shatrudhan Prajapati, Shikha Yadav, A. Singh et al. · 0 citations
Review Aug 2026

Therapeutic landscape of Parkinson's disease: Recent advances in saponin-mediated interventions.

Overall, saponins represent a promising avenue for the development of novel neuroprotective and disease-modifying therapies for PD, and challenges such as poor bioavailability in natural sources and limited access to brain remain significant barriers to clinical translation.

Debasmita Tripathy, Shreya Sen Sarma, Deepak Kumar et al. · 0 citations
Review Open access Aug 2026

Sesamum indicum-derived valdiate as a novel neuroprotective agent targeting PDE10A2 and SIRT1 in Huntington’s disease

Background Huntington’s disease is prevalent globally, with approximately 4.88 cases per 100,000 people, based on a systematic review and meta-analysis of 33 studies published between 2010 and 2022. Despite its significant prevalence, no proper treatment is available that directly addresses Huntington’s disease. The ex...

Mukul Shyam, M. D. Wafi Ismail, Deepak Sharma et al. · 0 citations
Review Jul 2026

Exploring the Therapeutic Potential of Chalcones in Alzheimer's Disease: Mechanistic Insights and SAR Perspectives.

Overall, chalcone-based MTDLs provide a rational framework for the development of next-generation anti-Alzheimer agents, highlighting the effects of hydroxylation, methoxylation, halogenation, halogenation, and heterocyclic hybridization on biological activity.

Deepika Paliwal, Aman Thakur · 0 citations
Review Aug 2026

Benzothiazole-Based Polyfunctional Agents in Alzheimer’s Therapy: Dual Diagnostic and Therapeutic Targeting of Aβ, Tau, and Neuroinflammation

Alzheimer's disease is known to be a multifaceted neurodegenerative disease, which includes events like amyloid-β (Aβ) plaque deposition, tau protein hyperphosphorylation, oxidative damage, neuroinflammation, and cholinergic dysfunction, for which the conventional pharmacotherapies only bring temporary symptomatic...

Meghana Devaraj, Prashant Tiwari, Sonal Dubey · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.